Description
Orion Biotechnology is developing a novel biologic for the treatment of SARS-CoV-2.
Amendment chain · 5 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $376,168 at start, $334,360 after amendment #4 (−$41,808).
- #02020-06-01$376,168
- #12021-01-18$376,168
- #22021-08-10$376,168
- #32022-01-28$376,168
- #42022-07-12$334,360-$41,808
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-06-01(start date) | $376,168 | — | Orion Biotechnology is developing a novel biologic for the treatment of SARS-CoV-2. |
| #1 amendment | 2021-01-18 | $376,168 | +$0 | Orion Biotechnology is developing a novel biologic for the treatment of SARS-CoV-2. |
| #2 amendment | 2021-08-10 | $376,168 | +$0 | Orion Biotechnology is developing a novel biologic for the treatment of SARS-CoV-2. |
| #3 amendment | 2022-01-28 | $376,168 | +$0 | Orion Biotechnology is developing a novel biologic for the treatment of SARS-CoV-2. |
| #4 amendment | 2022-07-12 | $334,360 | −$41,808 | Orion Biotechnology is developing a novel biologic for the treatment of SARS-CoV-2. |
Related records · 6
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 708721493)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2021-2022-Q3-978814 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $252,953 | FY2022 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q2-953967 · retrieved 2026-11-15.